Drug Trial Radar · NCT02514577
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Jan 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
217
Actual
Start
Nov 7, 2015
Primary completion
May 1, 2017
Study completion May 1, 2017
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
Conditions
- Plaque Psoriasis
Interventions
IDP-122 LotionDrug
Topical lotion
IDP-122 Vehicle LotionDrug
Topical lotion. No active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Success at Week 8Time frame: Week 8
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Valeant Site 11
Hot Springs, Arkansas
Valeant Site 1
Encinitas, California
Valeant Site 10
Encino, California
Valeant Site 12
Santa Rosa, California
Valeant Site 13
Atlanta, Georgia
Valeant Site 7
Boise, Idaho
Valeant Site 6
Rockville, Maryland
Valeant Site 4
Ann Arbor, Michigan
Valeant Site 8
Clarkston, Michigan
Valeant Site 15
Las Vegas, Nevada
Valeant Site 9
Raleigh, North Carolina
Valeant Site 5
Knoxville, Tennessee
Valeant Site 3
Austin, Texas
Valeant Site 2
San Antonio, Texas
Valeant Site 14
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.